• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study
【24h】

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

机译：由SQ标准化的草过敏免疫治疗片的季节内启动通常由具有过敏治疗经验的过敏专家和普通从业人员使用：一项非干预性观察研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionIntra-seasonal start of treatment with the SQ? grass sublingual immunotherapy (SLIT) tablet (GRAZAX?, ALK, Denmark) has been previously demonstrated to be well-tolerated. The objective of our study was to investigate the tolerability of intra-seasonal start of treatment comparing patients treated by allergists and general practitioners experienced in treatment of allergy (GPs). MethodsIn a non-interventional, open-label, observational study, data on intra-seasonal start with the SQ? grass SLIT tablet were recorded in patients treated by allergists and GPs in Germany. Adverse events (AEs) were recorded by the physicians at first administration and during the 1–3-month observation period. The tablets taken and any AEs were recorded by the patients in diaries for the first 14?days. ResultsTreatment with the SQ? grass SLIT tablet was started in 198 patients, and in 179 intra-seasonal (allergists: 140, GPs: 39) and 19 post-seasonal; average treatment period was 47?days. AEs related to intra-seasonal start were reported in 43.6% of patients; no relevant differences between allergists and GPs were observed. In the subgroup of GPs, patients were younger ( p =?0.0191), had more frequently asthma ( p =?0.0043), more patients used symptomatic medication in the previous pollen season ( p =?0.0198) and were more frequently treated for other diseases ( p =?0.0467). In the allergists subgroup, more diagnostic allergy tests were applied ( p ConclusionThe intra-seasonal start of treatment with the SQ? grass SLIT tablet in patients routinely treated by allergists or GPs with experience in treatment of allergy was well-tolerated, although patient characteristics were different with respect to age, frequency of asthma and concomitant allergies, use of symptomatic medication in the previous grass pollen season and concomitant treatment of other diseases. The safety profile from a previous placebo-controlled clinical trial and data from a previous real-life study on intra-seasonal start performed by allergists were confirmed.
机译：简介先前已证明SQ ？草舌舌免疫疗法（SLIT）片剂（GRAZAX ？，ALK，丹麦）在季节内开始治疗具有良好的耐受性。我们研究的目的是调查季节内开始治疗的耐受性，比较过敏者和有变态反应（GPs）治疗经验的全科医生治疗的患者。方法在一项非介入，开放标签的观察性研究中，记录了德国过敏症患者和全科医生治疗的SQ ？ grass SLIT片剂的季节内开始数据。首次给药时以及在1到3个月的观察期内，医师记录了不良事件（AE）。患者在头14天的日记中记录服用的药片和任何AE。结果198例患者开始使用SQ ？ grass SLIT片剂治疗，季节内有179例患者（过敏症患者：140例，全科医生：39例）和季节后19例;平均治疗时间为47天。有43.6％的患者报告了与季节内启动相关的不良事件;在过敏者和全科医生之间未观察到相关差异。在GP的亚组中，患者较年轻（p =？0.0191），哮喘发作频率更高（p =？0.0043），在前一个花粉季节使用对症药物治疗的患者更多（p =？0.0198），而对其他花粉季节的治疗则更频繁疾病（p =？0.0467）。在过敏症亚组中，应用了更多的诊断性过敏试验（p结论对于有过敏症治疗经验的过敏症或GP常规治疗的患者，SQ ？ grass SLIT片剂的季节内开始治疗效果良好耐受的，尽管患者的年龄，哮喘发作频率和伴随的变态反应，在以前的草花粉季节使用对症药物以及伴随其他疾病的治疗方面存在差异，安全性来自先前安慰剂对照的临床试验和数据先前由过敏学家进行的关于季节内启动的现实生活研究证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号